Wall Street analysts expect that Kadmon Holdings Inc (NYSE:KDMN) will post sales of $1.28 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Kadmon’s earnings, with the highest sales estimate coming in at $2.10 million and the lowest estimate coming in at $460,000.00. Kadmon posted sales of $1.46 million during the same quarter last year, which indicates a negative year over year growth rate of 12.3%. The firm is expected to issue its next earnings report on Tuesday, March 5th.

According to Zacks, analysts expect that Kadmon will report full year sales of $2.41 million for the current year, with estimates ranging from $1.62 million to $3.20 million. For the next fiscal year, analysts anticipate that the company will post sales of $4.19 million, with estimates ranging from $1.37 million to $7.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Kadmon.

Kadmon (NYSE:KDMN) last announced its quarterly earnings data on Friday, November 9th. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.09. The firm had revenue of $0.37 million during the quarter, compared to analyst estimates of $0.56 million. Kadmon had a negative return on equity of 253.82% and a negative net margin of 1,176.75%.

Several equities analysts have recently issued reports on the company. Zacks Investment Research upgraded Kadmon from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research report on Thursday, January 24th. ValuEngine downgraded Kadmon from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. WBB Securities raised Kadmon from a “sell” rating to a “hold” rating and set a $2.90 price target on the stock in a report on Wednesday, October 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Kadmon in a report on Monday, November 12th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. Kadmon has a consensus rating of “Buy” and an average target price of $11.08.

Shares of KDMN stock opened at $2.17 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 6.64 and a quick ratio of 6.58. Kadmon has a 52 week low of $1.88 and a 52 week high of $5.40. The company has a market capitalization of $252.28 million, a price-to-earnings ratio of -1.53 and a beta of 2.70.

Several institutional investors and hedge funds have recently made changes to their positions in KDMN. Schwab Charles Investment Management Inc. increased its holdings in shares of Kadmon by 730.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 173,830 shares of the company’s stock worth $694,000 after buying an additional 152,900 shares in the last quarter. Renaissance Technologies LLC bought a new position in Kadmon in the second quarter valued at approximately $1,026,000. Bank of New York Mellon Corp boosted its stake in Kadmon by 191.4% in the second quarter. Bank of New York Mellon Corp now owns 198,063 shares of the company’s stock valued at $790,000 after acquiring an additional 130,096 shares during the last quarter. BlackRock Inc. boosted its stake in Kadmon by 42.1% in the third quarter. BlackRock Inc. now owns 6,768,569 shares of the company’s stock valued at $22,606,000 after acquiring an additional 2,005,133 shares during the last quarter. Finally, Sofinnova Ventures Inc boosted its position in shares of Kadmon by 4.1% during the third quarter. Sofinnova Ventures Inc now owns 1,842,502 shares of the company’s stock worth $5,152,000 after purchasing an additional 72,919 shares in the last quarter. 71.17% of the stock is owned by institutional investors and hedge funds.

About Kadmon

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Featured Story: Cost of Capital Explained

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.